SNDX
Income statement / Annual
Last year (2024), Syndax Pharmaceuticals, Inc.'s total revenue was $23.68 M,
and the percentage change from the previous year is not available.
In 2024, Syndax Pharmaceuticals, Inc.'s net income was -$318.76 M.
See Syndax Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$23.68 M |
$0.00 |
$0.00 |
$139.71 M |
$1.52 M |
$1.52 M |
$1.52 M |
$2.11 M |
$1.22 M |
$627,000.00 |
| Cost of Revenue |
$826,000.00
|
$12,000.00
|
$454,000.00
|
$456,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$22.85 M
|
-$12,000.00
|
-$454,000.00
|
$139.25 M
|
$1.52 M
|
$1.52 M
|
$1.52 M
|
$2.11 M
|
$1.22 M
|
$627,000.00
|
| Gross Profit Ratio |
0.97
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$241.65 M
|
$163.02 M
|
$118.50 M
|
$88.25 M
|
$50.44 M
|
$42.99 M
|
$60.11 M
|
$48.20 M
|
$31.67 M
|
$9.55 M
|
| General & Administrative Expenses |
$120.88 M
|
$0.00
|
$33.26 M
|
$25.24 M
|
$22.51 M
|
$16.06 M
|
$17.29 M
|
$15.86 M
|
$13.32 M
|
$11.59 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$120.88 M
|
$66.92 M
|
$33.26 M
|
$25.24 M
|
$22.51 M
|
$16.06 M
|
$17.29 M
|
$15.86 M
|
$13.32 M
|
$11.59 M
|
| Other Expenses |
$0.00
|
$0.00
|
$2.42 M
|
-$1.29 M
|
-$1.74 M
|
$1.49 M
|
$1.92 M
|
$1.15 M
|
-$706,000.00
|
-$37,000.00
|
| Operating Expenses |
$362.53 M
|
$229.95 M
|
$151.76 M
|
$113.49 M
|
$72.94 M
|
$59.06 M
|
$77.39 M
|
$64.06 M
|
$44.99 M
|
$21.14 M
|
| Cost And Expenses |
$363.35 M
|
$229.95 M
|
$151.76 M
|
$113.49 M
|
$72.94 M
|
$59.06 M
|
$77.39 M
|
$64.06 M
|
$44.99 M
|
$21.14 M
|
| Interest Income |
$26.09 M
|
$21.16 M
|
$5.87 M
|
$403,000.00
|
$841,000.00
|
$1.57 M
|
$0.00
|
$0.00
|
$0.00
|
$161,000.00
|
| Interest Expense |
$4.93 M
|
$208,000.00
|
$3.14 M
|
$1.90 M
|
$2.36 M
|
$1.57 M
|
$1.94 M
|
$1.42 M
|
$956,000.00
|
$1.58 M
|
| Depreciation & Amortization |
$8,000.00
|
$12,000.00
|
$454,000.00
|
$456,000.00
|
$515,000.00
|
$451,000.00
|
$78,000.00
|
$76,000.00
|
$89,000.00
|
$21,000.00
|
| EBITDA |
-$313.82 M |
-$229.94 M |
-$151.76 M |
$27.28 M |
-$70.29 M |
-$55.60 M |
-$73.88 M |
-$61.88 M |
-$43.68 M |
-$20.49 M |
| EBITDA Ratio |
-13.25
|
0
|
0
|
0.19
|
-47.08
|
-37.93
|
-50.02
|
-29.39
|
-35.87
|
-32.48
|
| Operating Income Ratio |
-14.34
|
0
|
0
|
0.19
|
-47.08
|
-37.93
|
-50.02
|
-29.39
|
-35.87
|
-32.72
|
| Total Other Income/Expenses Net |
$20.91 M
|
$20.59 M
|
$2.42 M
|
-$1.29 M
|
-$1.74 M
|
$1.49 M
|
$1.92 M
|
$1.15 M
|
-$706,000.00
|
-$3.61 M
|
| Income Before Tax |
-$318.76 M
|
-$209.36 M
|
-$149.34 M
|
$24.93 M
|
-$73.16 M
|
-$56.05 M
|
-$73.96 M
|
-$60.80 M
|
-$44.47 M
|
-$24.12 M
|
| Income Before Tax Ratio |
-13.46
|
0
|
0
|
0.18
|
-48.23
|
-36.95
|
-48.75
|
-28.84
|
-36.45
|
-38.47
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$5.59 M
|
-$43,000.00
|
-$89,000.00
|
-$92,000.00
|
$1.92 M
|
-$76,000.00
|
-$89,000.00
|
$1.54 M
|
| Net Income |
-$318.76 M
|
-$209.36 M
|
-$143.75 M
|
$24.93 M
|
-$73.07 M
|
-$55.96 M
|
-$73.96 M
|
-$60.80 M
|
-$44.47 M
|
-$24.12 M
|
| Net Income Ratio |
-13.46
|
0
|
0
|
0.18
|
-48.17
|
-36.89
|
-48.75
|
-28.84
|
-36.45
|
-38.47
|
| EPS |
-3.73 |
-2.98 |
-2.37 |
0.48 |
-1.77 |
-1.84 |
-2.92 |
-2.9 |
-3.04 |
-1.39 |
| EPS Diluted |
-3.73 |
-2.98 |
-2.37 |
0.46 |
-1.77 |
-1.84 |
-2.92 |
-2.9 |
-3.04 |
-1.39 |
| Weighted Average Shares Out |
$85.43 M
|
$70.26 M
|
$60.76 M
|
$52.06 M
|
$41.31 M
|
$30.49 M
|
$25.37 M
|
$21.00 M
|
$14.62 M
|
$17.37 M
|
| Weighted Average Shares Out Diluted |
$85.43 M
|
$70.37 M
|
$60.76 M
|
$53.62 M
|
$41.31 M
|
$30.49 M
|
$25.37 M
|
$21.00 M
|
$14.62 M
|
$17.37 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
